155 related articles for article (PubMed ID: 2698855)
1. Liposomal amphotericin-B in the control of experimental aspergillosis in mice: Part I--Relative therapeutic efficacy of free and liposomal amphotericin-B.
Ahmad I; Sarkar AK; Bachhawat BK
Indian J Biochem Biophys; 1989 Dec; 26(6):351-6. PubMed ID: 2698855
[TBL] [Abstract][Full Text] [Related]
2. Effect of cholesterol in various liposomal compositions on the in vivo toxicity, therapeutic efficacy, and tissue distribution of amphotericin B.
Ahmad I; Sarkar AK; Bachhawat BK
Biotechnol Appl Biochem; 1990 Oct; 12(5):550-6. PubMed ID: 2288711
[TBL] [Abstract][Full Text] [Related]
3. Liposomal hamycin in the control of experimental aspergillosis in mice: relative toxicity, therapeutic efficacy and tissue distribution of free and liposomal hamycin.
Moonis M; Ahmad I; Bachhawat BK
Indian J Biochem Biophys; 1992 Aug; 29(4):339-45. PubMed ID: 1427960
[TBL] [Abstract][Full Text] [Related]
4. Liposomal amphotericin-B as a therapeutic measure to control experimental aspergillosis in BALB/c mice.
Ahmad I; Sarkar AK; Bachhawat BK
Indian J Biochem Biophys; 1990 Dec; 27(6):370-4. PubMed ID: 2102483
[No Abstract] [Full Text] [Related]
5. Therapeutic and hemolytic evaluation of in-situ liposomal preparation containing amphotericin - beta complexed with different chemically modified beta - cyclodextrins.
Chakraborty KK; Naik SR
J Pharm Pharm Sci; 2003; 6(2):231-7. PubMed ID: 12935435
[TBL] [Abstract][Full Text] [Related]
6. Toxicity, stability and pharmacokinetics of amphotericin B in immunomodulator tuftsin-bearing liposomes in a murine model.
Khan MA; Owais M
J Antimicrob Chemother; 2006 Jul; 58(1):125-32. PubMed ID: 16709592
[TBL] [Abstract][Full Text] [Related]
7. Design of liposomes to improve delivery of amphotericin-B in the treatment of aspergillosis.
Ahmad I; Sarkar AK; Bachhawat BK
Mol Cell Biochem; 1989 Nov 23-Dec 19; 91(1-2):85-90. PubMed ID: 2695834
[TBL] [Abstract][Full Text] [Related]
8. Mannosylated liposomes as carriers for hamycin in the treatment of experimental aspergillosis in Balb/C mice.
Moonis M; Ahmad I; Bachhawat BK
J Drug Target; 1993; 1(2):147-55. PubMed ID: 8069553
[TBL] [Abstract][Full Text] [Related]
9. Comparative study on the efficacy of AmBisome and Fungizone in a mouse model of pulmonary aspergillosis.
Takemoto K; Yamamoto Y; Ueda Y; Sumita Y; Yoshida K; Niki Y
J Antimicrob Chemother; 2006 Apr; 57(4):724-31. PubMed ID: 16446374
[TBL] [Abstract][Full Text] [Related]
10. Liposomal amphotericin B in three lung transplant recipients. The Groningen Lung Transplantation Group.
Mannes GP; van der Bij W; de Boer WJ
J Heart Lung Transplant; 1995; 14(4):781-4. PubMed ID: 7578189
[TBL] [Abstract][Full Text] [Related]
11. Preclinical & pharmaceutical testing of liposomal amphotericin B.
Gokhale PC; Kotwani RN; Dange SY; Kshirsagar NA; Pandya SK
Indian J Med Res; 1993 Apr; 98():75-8. PubMed ID: 8344735
[TBL] [Abstract][Full Text] [Related]
12. Combination antifungal therapy of murine aspergillosis: liposomal amphotericin B and micafungin.
Graybill JR; Bocanegra R; Gonzalez GM; Najvar LK
J Antimicrob Chemother; 2003 Oct; 52(4):656-62. PubMed ID: 12972452
[TBL] [Abstract][Full Text] [Related]
13. The role of liposomal amphotericin B in the treatment of systemic fungal infections.
Patterson TF; Andriole VT
Eur J Cancer Clin Oncol; 1989; 25 Suppl 2():S63-8. PubMed ID: 2693111
[TBL] [Abstract][Full Text] [Related]
14. [Treatment of experimental invasive pulmonary aspergillosis in rats with liposomal amphotericin B].
Matsuda H; Kohno S; Miyazaki Y; Mitsutake K; Tanaka K; Maesaki S; Iwamoto M; Hashimoto A; Kaku M; Koga H
Kansenshogaku Zasshi; 1993 Feb; 67(2):102-9. PubMed ID: 8468494
[TBL] [Abstract][Full Text] [Related]
15. Incorporation of amphotericin B in tuftsin-bearing liposomes showed enhanced efficacy against systemic cryptococcosis in leucopenic mice.
Khan MA; Nasti TH; Owais M
J Antimicrob Chemother; 2005 Oct; 56(4):726-31. PubMed ID: 16126780
[TBL] [Abstract][Full Text] [Related]
16. Activity of micafungin (FK463) against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating in vivo resistance to amphotericin B.
Warn PA; Morrissey G; Morrissey J; Denning DW
J Antimicrob Chemother; 2003 Apr; 51(4):913-9. PubMed ID: 12654746
[TBL] [Abstract][Full Text] [Related]
17. Effect of elimination of phagocytic cells by liposomal dichloromethylene diphosphonate on aspergillosis virulence and toxicity of liposomal amphotericin B in mice.
Moonis M; Ahmad I; Bachhawat BK
J Antimicrob Chemother; 1994 Mar; 33(3):571-83. PubMed ID: 8040121
[TBL] [Abstract][Full Text] [Related]
18. Distribution of amphotericin B-arabinogalactan conjugate in mouse tissue and its therapeutic efficacy against murine aspergillosis.
Falk R; Grunwald J; Hoffman A; Domb AJ; Polacheck I
Antimicrob Agents Chemother; 2004 Sep; 48(9):3606-9. PubMed ID: 15328139
[TBL] [Abstract][Full Text] [Related]
19. Liposomal amphotericin B activates antifungal resistance with reduced toxicity by diverting Toll-like receptor signalling from TLR-2 to TLR-4.
Bellocchio S; Gaziano R; Bozza S; Rossi G; Montagnoli C; Perruccio K; Calvitti M; Pitzurra L; Romani L
J Antimicrob Chemother; 2005 Feb; 55(2):214-22. PubMed ID: 15649994
[TBL] [Abstract][Full Text] [Related]
20. [An experimental study of the therapeutic effect of interleukin-2 and interleukin-12 with and without amphotericin B on pulmonary fungal infection].
Zhang CR; Tang YC; Kawakami K; Zhang TT; Zhang KX; Zhu JX
Zhonghua Jie He He Hu Xi Za Zhi; 2004 Apr; 27(4):234-6. PubMed ID: 15144612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
